TVTX - Leadership updates

Meissa Vaccines ("Meissa"), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development. Martin Moore, Ph.D., cofounder of Meissa, will serve as the Company's Chief Scientific Officer. "I am excited to welcome Frank to the Meissa leadership team," said Dr. Moore. "We are at an important stage in Meissa's growth, and Frank brings extensive, complementary experience in commercial planning, business developm

Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution and global regulatory engagement. Dr. Inrig joins the Company as it prepares for accelerated approval submissions of sparsentan for IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) in 2022, as well as the continued advancement of its pegtibatinase program in classical homocystinuria (HCU). "We are excited to welcome Jula to the Travere Therapeutics

SAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the appointment of Ruth Williams-Brinkley to the Company's Board of Directors, effective immediately. Ms. Williams-Brinkley brings to Travere more than 35 years of executive leadership in care delivery and health plan operations. "On behalf of the Board of Directors, I am pleased to welcome Ruth to Travere," said Gary Lyons, chairman of the Travere Therapeutics Board of Directors. "She is a distinguished leader with extensive experience in the delivery of care and is an actively engaged and admired community leader. As we look to future potential commercial launches from our pipeline, Ru